http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 22 Jul 2026 07:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Zai+Lab+to+Announce+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates+on+August+6%2C+2026/26798286.html <p> - <i>Company to host conference call and webcast on August 6, 2026, at 8:00 a.m. ET (8:00 p.m. HKT)</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced<b> </b>that it will report its second quarter 2026 financial results and provide recent corporate updates on August 6, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT). </p><p> <strong>Conference Call and Webcast Information</strong> </p><p> The live webcast can be accessed by visiting the Company's website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.zailaboratory.com&amp;esheet=54574908&amp;newsitemid=20260722102764&amp;lan=en-US&amp;anchor=http%3A%2F%2Fir.zailaboratory.com&amp;index=1&amp;md5=95645b73e4e04ac96d5a020aa10d801c" shape="rect">http://ir.zailaboratory.com</a>. Participants must register in http://www.streetinsider.com/Press+Releases/Zai+Lab+to+Announce+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates+on+August+6%2C+2026/26798286.html Wed, 22 Jul 2026 07:30:00 -0400 1ZLB 9688 A.05323225 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+to+Announce+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates+on+August+6%2C+2026/26798286.html <p> - <i>Company to host conference call and webcast on August 6, 2026, at 8:00 a.m. ET (8:00 p.m. HKT)</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced<b> </b>that it will report its second quarter 2026 financial results and provide recent corporate updates on August 6, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT). </p><p> <strong>Conference Call and Webcast Information</strong> </p><p> The live webcast can be accessed by visiting the Company's website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.zailaboratory.com&amp;esheet=54574908&amp;newsitemid=20260722102764&amp;lan=en-US&amp;anchor=http%3A%2F%2Fir.zailaboratory.com&amp;index=1&amp;md5=95645b73e4e04ac96d5a020aa10d801c" shape="rect">http://ir.zailaboratory.com</a>. Participants must register in http://www.streetinsider.com/Press+Releases/Zai+Lab+to+Announce+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates+on+August+6%2C+2026/26798286.html Wed, 22 Jul 2026 07:30:00 -0400 1ZLB 9688 A.05323225 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+to+Announce+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates+on+August+6%2C+2026/26798286.html <p> - <i>Company to host conference call and webcast on August 6, 2026, at 8:00 a.m. ET (8:00 p.m. HKT)</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced<b> </b>that it will report its second quarter 2026 financial results and provide recent corporate updates on August 6, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT). </p><p> <strong>Conference Call and Webcast Information</strong> </p><p> The live webcast can be accessed by visiting the Company's website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.zailaboratory.com&amp;esheet=54574908&amp;newsitemid=20260722102764&amp;lan=en-US&amp;anchor=http%3A%2F%2Fir.zailaboratory.com&amp;index=1&amp;md5=95645b73e4e04ac96d5a020aa10d801c" shape="rect">http://ir.zailaboratory.com</a>. Participants must register in http://www.streetinsider.com/Press+Releases/Zai+Lab+to+Announce+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates+on+August+6%2C+2026/26798286.html Wed, 22 Jul 2026 07:30:00 -0400 1ZLB 9688 A.05323225 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+to+Announce+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates+on+August+6%2C+2026/26798286.html <p> - <i>Company to host conference call and webcast on August 6, 2026, at 8:00 a.m. ET (8:00 p.m. HKT)</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced<b> </b>that it will report its second quarter 2026 financial results and provide recent corporate updates on August 6, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT). </p><p> <strong>Conference Call and Webcast Information</strong> </p><p> The live webcast can be accessed by visiting the Company's website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.zailaboratory.com&amp;esheet=54574908&amp;newsitemid=20260722102764&amp;lan=en-US&amp;anchor=http%3A%2F%2Fir.zailaboratory.com&amp;index=1&amp;md5=95645b73e4e04ac96d5a020aa10d801c" shape="rect">http://ir.zailaboratory.com</a>. Participants must register in http://www.streetinsider.com/Press+Releases/Zai+Lab+to+Announce+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates+on+August+6%2C+2026/26798286.html Wed, 22 Jul 2026 07:30:00 -0400 1ZLB 9688 A.05323225 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+to+Announce+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates+on+August+6%2C+2026/26798286.html <p> - <i>Company to host conference call and webcast on August 6, 2026, at 8:00 a.m. ET (8:00 p.m. HKT)</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced<b> </b>that it will report its second quarter 2026 financial results and provide recent corporate updates on August 6, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT). </p><p> <strong>Conference Call and Webcast Information</strong> </p><p> The live webcast can be accessed by visiting the Company's website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.zailaboratory.com&amp;esheet=54574908&amp;newsitemid=20260722102764&amp;lan=en-US&amp;anchor=http%3A%2F%2Fir.zailaboratory.com&amp;index=1&amp;md5=95645b73e4e04ac96d5a020aa10d801c" shape="rect">http://ir.zailaboratory.com</a>. Participants must register in http://www.streetinsider.com/Press+Releases/Zai+Lab+to+Announce+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates+on+August+6%2C+2026/26798286.html Wed, 22 Jul 2026 07:30:00 -0400 1ZLB 9688 A.05323225 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+to+Announce+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates+on+August+6%2C+2026/26798286.html <p> - <i>Company to host conference call and webcast on August 6, 2026, at 8:00 a.m. ET (8:00 p.m. HKT)</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced<b> </b>that it will report its second quarter 2026 financial results and provide recent corporate updates on August 6, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT). </p><p> <strong>Conference Call and Webcast Information</strong> </p><p> The live webcast can be accessed by visiting the Company's website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.zailaboratory.com&amp;esheet=54574908&amp;newsitemid=20260722102764&amp;lan=en-US&amp;anchor=http%3A%2F%2Fir.zailaboratory.com&amp;index=1&amp;md5=95645b73e4e04ac96d5a020aa10d801c" shape="rect">http://ir.zailaboratory.com</a>. Participants must register in http://www.streetinsider.com/Press+Releases/Zai+Lab+to+Announce+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates+on+August+6%2C+2026/26798286.html Wed, 22 Jul 2026 07:30:00 -0400 1ZLB 9688 A.05323225 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+to+Announce+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates+on+August+6%2C+2026/26798286.html <p> - <i>Company to host conference call and webcast on August 6, 2026, at 8:00 a.m. ET (8:00 p.m. HKT)</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced<b> </b>that it will report its second quarter 2026 financial results and provide recent corporate updates on August 6, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT). </p><p> <strong>Conference Call and Webcast Information</strong> </p><p> The live webcast can be accessed by visiting the Company's website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.zailaboratory.com&amp;esheet=54574908&amp;newsitemid=20260722102764&amp;lan=en-US&amp;anchor=http%3A%2F%2Fir.zailaboratory.com&amp;index=1&amp;md5=95645b73e4e04ac96d5a020aa10d801c" shape="rect">http://ir.zailaboratory.com</a>. Participants must register in http://www.streetinsider.com/Business+Wire/Zai+Lab+to+Announce+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates+on+August+6%2C+2026/26798286.html Wed, 22 Jul 2026 07:30:00 -0400 1ZLB 9688 A.05323225 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+to+Announce+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates+on+August+6%2C+2026/26798286.html <p> - <i>Company to host conference call and webcast on August 6, 2026, at 8:00 a.m. ET (8:00 p.m. HKT)</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced<b> </b>that it will report its second quarter 2026 financial results and provide recent corporate updates on August 6, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT). </p><p> <strong>Conference Call and Webcast Information</strong> </p><p> The live webcast can be accessed by visiting the Company's website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.zailaboratory.com&amp;esheet=54574908&amp;newsitemid=20260722102764&amp;lan=en-US&amp;anchor=http%3A%2F%2Fir.zailaboratory.com&amp;index=1&amp;md5=95645b73e4e04ac96d5a020aa10d801c" shape="rect">http://ir.zailaboratory.com</a>. Participants must register in http://www.streetinsider.com/Business+Wire/Zai+Lab+to+Announce+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates+on+August+6%2C+2026/26798286.html Wed, 22 Jul 2026 07:30:00 -0400 1ZLB 9688 A.05323225 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+to+Announce+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates+on+August+6%2C+2026/26798286.html <p> - <i>Company to host conference call and webcast on August 6, 2026, at 8:00 a.m. ET (8:00 p.m. HKT)</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced<b> </b>that it will report its second quarter 2026 financial results and provide recent corporate updates on August 6, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT). </p><p> <strong>Conference Call and Webcast Information</strong> </p><p> The live webcast can be accessed by visiting the Company's website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.zailaboratory.com&amp;esheet=54574908&amp;newsitemid=20260722102764&amp;lan=en-US&amp;anchor=http%3A%2F%2Fir.zailaboratory.com&amp;index=1&amp;md5=95645b73e4e04ac96d5a020aa10d801c" shape="rect">http://ir.zailaboratory.com</a>. Participants must register in http://www.streetinsider.com/Business+Wire/Zai+Lab+to+Announce+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates+on+August+6%2C+2026/26798286.html Wed, 22 Jul 2026 07:30:00 -0400 1ZLB 9688 A.05323225 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+to+Announce+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates+on+August+6%2C+2026/26798286.html <p> - <i>Company to host conference call and webcast on August 6, 2026, at 8:00 a.m. ET (8:00 p.m. HKT)</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced<b> </b>that it will report its second quarter 2026 financial results and provide recent corporate updates on August 6, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT). </p><p> <strong>Conference Call and Webcast Information</strong> </p><p> The live webcast can be accessed by visiting the Company's website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.zailaboratory.com&amp;esheet=54574908&amp;newsitemid=20260722102764&amp;lan=en-US&amp;anchor=http%3A%2F%2Fir.zailaboratory.com&amp;index=1&amp;md5=95645b73e4e04ac96d5a020aa10d801c" shape="rect">http://ir.zailaboratory.com</a>. Participants must register in http://www.streetinsider.com/Business+Wire/Zai+Lab+to+Announce+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates+on+August+6%2C+2026/26798286.html Wed, 22 Jul 2026 07:30:00 -0400 1ZLB 9688 A.05323225 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+to+Announce+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates+on+August+6%2C+2026/26798286.html <p> - <i>Company to host conference call and webcast on August 6, 2026, at 8:00 a.m. ET (8:00 p.m. HKT)</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced<b> </b>that it will report its second quarter 2026 financial results and provide recent corporate updates on August 6, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT). </p><p> <strong>Conference Call and Webcast Information</strong> </p><p> The live webcast can be accessed by visiting the Company's website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.zailaboratory.com&amp;esheet=54574908&amp;newsitemid=20260722102764&amp;lan=en-US&amp;anchor=http%3A%2F%2Fir.zailaboratory.com&amp;index=1&amp;md5=95645b73e4e04ac96d5a020aa10d801c" shape="rect">http://ir.zailaboratory.com</a>. Participants must register in http://www.streetinsider.com/Business+Wire/Zai+Lab+to+Announce+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates+on+August+6%2C+2026/26798286.html Wed, 22 Jul 2026 07:30:00 -0400 1ZLB 9688 A.05323225 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+to+Announce+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates+on+August+6%2C+2026/26798286.html <p> - <i>Company to host conference call and webcast on August 6, 2026, at 8:00 a.m. ET (8:00 p.m. HKT)</i> </p> <p> SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced<b> </b>that it will report its second quarter 2026 financial results and provide recent corporate updates on August 6, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT). </p><p> <strong>Conference Call and Webcast Information</strong> </p><p> The live webcast can be accessed by visiting the Company's website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.zailaboratory.com&amp;esheet=54574908&amp;newsitemid=20260722102764&amp;lan=en-US&amp;anchor=http%3A%2F%2Fir.zailaboratory.com&amp;index=1&amp;md5=95645b73e4e04ac96d5a020aa10d801c" shape="rect">http://ir.zailaboratory.com</a>. Participants must register in http://www.streetinsider.com/Business+Wire/Zai+Lab+to+Announce+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates+on+August+6%2C+2026/26798286.html Wed, 22 Jul 2026 07:30:00 -0400 1ZLB 9688 A.05323225 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Press+Releases/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html <p> - <i>European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) <br></br></i>- <i>SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options <br></br></i>- <i>EMA designation for zoci in </i><i>pulmonary </i><i>NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the </i><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.zailaboratory.com%2Fnews-releases%2Fnews-release-details%2Fzai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan&amp;esheet=54554312&amp;newsitemid=20260616338405&amp;lan=en-US&amp;anchor=AACR+Annual+Meeting+in+April+2026&amp;index=1&amp;md5=1ec083fef54637c7b80636612a58e352" shape="rect">AACR Annual Meeting in April 2026</a> </p> <p> http://www.streetinsider.com/Business+Wire/Zai+Lab+Receives+EMA+Orphan+Drug+Designation+for+Zocilurtatug+Pelitecan+%28Zoci%29+in+Pulmonary+Neuroendocrine+Carcinomas/26650207.html Tue, 16 Jun 2026 07:00:00 -0400 1ZLB 9688 A.05323225 A.06822034 A.31066700 O.20026344 O.22422661 O.22443941 O.34841441 ZLAB